Selected Platelet Aggregation Inhibitors/NSAIDs; Salicylates Interactions

This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.

Medical warning:

Serious. These medicines may interact and cause very harmful effects. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.

How the interaction occurs:

Platelet aggregation inhibitors and NSAIDs decrease your body's ability to make clots.

What might happen:

You may experience an increased chance for bleeding including bleeding from your gums, nosebleeds, unusual bruising, or dark stools.

What you should do about this interaction:

Let your healthcare professionals (e.g. doctor or pharmacist) know that you are taking these two medicines together. They may already may be aware of this interaction and may be monitoring you for it. If your doctor prescribes these medicines together, you may need to check your bleeding times more often. Do not start, stop, or change the dosage of any medicine before checking with them first. Let your doctor know right away if you have any symptoms of bleeding.

  • 1.ReoPro (abciximab) US prescribing information. Eli Lilly and Company November 25, 2013.
  • 2.Kengreal (cangrelor) US prescribing information. The Medicines Company October, 2019.
  • 3.Plavix (clopidogrel hydrogen sulfate) Australian prescribing information. Sanofi-Synthelabo Australia Pty Limited May, 2022.
  • 4.Plavix (clopidogrel hydrogen sulphate) UK summary of product characteristics. Sanofi Pharma Bristol-Myers Squibb SNC July 23, 2020.
  • 5.Plavix (clopidogrel bisulfate) US prescribing information. Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership September, 2022.
  • 6.Integrilin (eptifibatide) US prescribing information. Schering Corporation March, 2011.
  • 7.Abraham NS, et al. ACCF-ACG-AHA 2010 Expert Consensus Document on the concomitant use of proton pump inhibitors & thienopyridines: a focused update of the ACCF-ACG-AHA 2008 expert consensus document. Circulation 2010 Dec 14;122(24):2619-33.
  • 8.Kang DO, An H, Park GU, Yum Y, Park EJ, Park Y, Jang WY, Kim W, Choi JY, Roh SY, Na JO, Kim JW, Kim EJ, Rha SW, Park CG, Seo HS, Choi CU. Cardiovascular and Bleeding Risks Associated With Nonsteroidal Anti-Inflammatory Drugs After Myocardial Infarction. J Am Coll Cardiol 2020 Aug 4;76(5):518-529.

Selected from data included with permission and copyrighted by First Databank, Inc. This copyrighted material has been downloaded from a licensed data provider and is not for distribution, except as may be authorized by the applicable terms of use.

CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.